Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study observed that in four middle-aged men with ejaculation disorders, therapy with human chorionic gonadotropin (hCG) alone or combined with recombinant follicle-stimulating hormone (rFSH) improved sexual desire, semen volume, and various other symptoms, although some experienced elevated estradiol levels and hair loss.

This review details the prevalence and management of ejaculatory disorders in men with benign prostatic hyperplasia-related urinary symptoms and highlights the importance of preserving peri-montanal tissue during treatment to maintain antegrade ejaculation.

This review discusses the sexual side effects of finasteride and dutasteride, two 5-α-reductase inhibitors, and reports no new clinical findings while calling for further research into dosage differences.

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

Using hair loss drugs finasteride and dutasteride may cause sexual side effects.

In this study, patients who were informed about finasteride's sexual side effects reported them significantly more often than those who were not, highlighting a potential nocebo effect.

Finasteride can cause sexual side effects like decreased libido and erectile dysfunction.

This meta-analysis reported that dutasteride was more effective than finasteride in increasing hair count and improving visual hair appearance in men with androgenetic alopecia over a 24-week period, while both drugs had similar rates of sexual dysfunction side effects.

This review presents studies on plants used in Mexico to treat alopecia and reports no new clinical results.

This study found that patients using finasteride were up to twice as likely to experience sexual dysfunction, including ejaculation disorder, decreased libido, and impotence, compared to those not using the drug.

This review discusses the use of finasteride for treating androgenetic alopecia in men, noting its effectiveness in maintaining and regrowing hair on the scalp and top of the head.

This study observed enduring sexual dysfunction reported in 300 cases globally following the use of SSRIs, finasteride, and isotretinoin, with common symptoms like genital anaesthesia and loss of libido.

This study found that among ten identified medications associated with ejaculatory disorders, Paroxetine and Tamsulosin were mainly linked to delayed and retrograde ejaculation, while Finasteride and Sildenafil were most associated with painful ejaculation and ejaculation failure according to reports from FDA-FAERS and Eudra-Vigilance databases.

This case study of a subfertile couple highlighted the importance of considering haemochromatosis, particularly involving the C282Y mutation of the HFE gene, in patients with endocrine disorders linked to hypogonadism.

Man experienced post-finasteride syndrome symptoms after using finasteride and dutasteride for hair loss.

This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.

This review examined studies on erectile dysfunction and 5 alpha-reductase inhibitors, concluding that these drugs do not significantly cause erectile dysfunction and emphasizing testosterone's importance over dihydrotestosterone in erectile function.

This study found that finasteride 1 mg daily significantly increased hair density and improved appearance in men with androgenetic alopecia, with 66% showing visibly thicker hair after two years compared to 7% in the placebo group.

This article reviews changes in men's sexual health after midlife, exploring physiologic changes, psychological factors, and various treatment options, but it presents no new clinical results.

This study found that finasteride delivered through a nano-transferosomal gel showed improved penetration through skin layers compared to a conventional gel, suggesting a potential alternative for oral administration.

This review discusses the pathophysiology of delayed ejaculation, highlighting the role of various biogenic and psychogenic factors, but reports no new clinical findings.

Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.

This paper discusses the first reported case of post-finasteride syndrome in a long-term dermatotrichology setting, occurring in a 25-year-old male after dutasteride treatment, and highlights possible links to mental health disorders.

This paper discusses the use of lifestyle drugs by individuals without medical conditions to enhance appearance, highlighting that such usage may worsen emotional disorders and suggests these should be treated with psychotherapy or psychopharmacotherapy.

This article reviews the spectrum of connective tissue disorders and discusses the role of autoantibodies, particularly in lupus erythematosus, but reports no new findings.

This paper reviews the growing use of psychotropic drugs in dermatology due to the link between mental states and skin conditions but does not present new clinical findings.

This study suggests that inhibitors of steroidogenic enzymes may have therapeutic potential for certain behavioral disorders linked to dopaminergic hyperfunction, despite concerns about their endocrine impacts.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This study reports that prostatitis, affecting many men aged 30 to 50, arises from diverse causes, including bacterial infections and pelvic pain syndromes, and requires treatment strategies specific to its type, such as antibiotics and lifestyle changes.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.